Aim: To investigate the potential effects of Y-QA31, a novel dopamine D 3 receptor antagonist, as an antipsychotic drug. Methods: A panel of radioligand-receptor binding assays was performed to identify the affinities of Y-QA31 for different G proteincoupled receptors. [
Introduction
Schizophrenia is an intractable neuropsychiatric disorder characterized by positive (delusions and hallucinations) and negative (social withdrawal, blunted affect, and mutism) symptoms, as well as cognitive deficits (deficits in attention, working and verbal memory, and executive function). Dopaminergic systems play a dominant role in regulating the development of schizophrenia, and therefore, dopamine receptors have been the primary target for antipsychotic research [1] . 2 -like receptors that inhibit adenylyl cyclase through coupling with the G i/o -protein [2] . Blocking dopamine D 2 receptors (D 2 R) with haloperidol successfully alleviates positive symptoms. However, this treatment shows limited effectiveness on negative and cognitive symptoms [3, 4] . Moreover, haloperidol causes severe side effects, such as extrapyramidal reactions and tardive dyskinesia, which lead to patients' non-compliance to these medications [3, 4] . In contrast to D 2 R, dopamine D 3 receptors (D 3 R) are found important for psychotic disorders in the brain regions such as the nucleus accumbens (NAc), the thalamus, and the cortex [5] , while D 3 R distribute less in the striatum, the brain region associated with movement function. Therefore, the antipsychotic compounds targeting D 3 R cause less extrapyramidal www.chinaphar.com Sun X et al Acta Pharmacologica Sinica npg side effects than those targeting D 2 R. Previous studies have suggested that the prefrontal cortex was associated with the occurrence of negative symptoms as well as the cognitive impairment of schizophrenia. In the D 3 R-KO mice, cognitive performance was enhanced [6, 7] , suggesting that D 3 R has a regulating effect in schizophrenia, especially in its cognitive and negative symptoms. In addition, Shaikh and colleagues reported that in a study of 133 Caucasian subjects the Ser9 D 3 allele was associated with susceptibility to schizophrenia [8] . The autopsy study found that the density of D 3 R in the ventral striatum increased significantly in patients with schizophrenia but remained relatively normal in patients treated with antipsychotic drugs, further suggesting the important role of D 3 R in the development of schizophrenia. Therefore, D 3 R has been considered as a potential target for antipsychotic agents.
Several D 3 R antagonists have been developed. Among them, some selective D 3 R antagonists, such as S33084 [9] and SB-277011A (D 3 /D 2 selectivity=112) [10] , are not as effective as the D 2 R antagonist L741,626 [11] in reducing positive symptoms in animal models, such as amphetamine-induced hyperlocomotion and the impaired prepulse inhibition (PPI) induced by apomorphine. The preferential D 3 R antagonist S33138 (D 3 /D 2 selectivity=25) potently alleviates the positive, negative and cognitive symptoms of schizophrenia [12] . Because of the pharmacological properties of these compounds, however, their effects cannot be attributed solely to D 3 R, and a selective D 3 R antagonist is still needed to identify the effects of D 3 R on the symptoms of schizophrenia.
In the current study, we evaluated Y-QA31, a novel and selective D 3 R antagonist (D 3 /D 2 selectivity=186) with medium affinity to the 5-HT 1A receptor and the α 1A adrenoceptor. Because the blocking of D 3 versus D 2 receptors is debated in the treatment of various symptoms of schizophrenia, we investigated the effects of Y-QA31 in animal models with positive and cognitive symptoms and analyzed its ability to induce catalepsy in mice to assess the potential of Y-QA31 as an antipsychotic drug.
Materials and methods

Materials
All radioligands used in our experiments were purchased from PerkinElmer Life Sciences (NEN, Boston, MA, USA). Other drugs used in the experiments were obtained from Sigma (St Louis, MO, USA). Y-QA31 (N-N-(4-(4-(2-methoxyphenyl) piperazin-1-yl)butyl)-2-benzothiazolinone-6-carboxamide hydrochloride), the chemical structure as shown in Figure 1 , was synthesized at the Beijing Institute of Pharmacology and Toxicology and was dissolved in 25% 2-hydroxypropyl-cyclodextrin (Sigma, St Louis, MO, USA). hD 4 R-, hD 5 R-, h5-HT 1A R-, h5-HT 1B R-, h5-HT 1D R-, h5-HT 2A R-, h5-HT 2C R-, h5-HT 5A R-, h5-HT 6 R-, hA 1 R-, hA 2A R-, hH 1 R-, hH 2 R-, hH 3 R-, hCB 1 R-, hCB 2 R-, hα 2A -, and hM 2 R-pcDNA3.1(+) plasmids were purchased from Missouri S&T cDNA Resource Center (Rolla, MO, USA).
Animals
Male CD1 mice (weighing 18-22 g) and SD rats (weighing 180-220 g) were obtained from the Beijing Animal Center.
The mice were maintained in cages with unrestricted access to food and water at 21±1 °C, 60%±5% humidity, and under a 12-h light/dark cycle. All protocols in this study were approved by the Committee of Animal Use and Protection of the Beijing Institute of Pharmacology and Toxicology.
In vitro studies on Y-QA31 Radioligand-receptor binding assays were performed to identify the affinity of Y-QA31 for G protein-coupled receptors, [
35
S]
GTPγS-binding assays and intracellular calcium assays were performed to identify the intrinsic activity of Y-QA31. The protocols were performed according to previous reports [3, [13] [14] [15] , with some modifications.
Radioligand-receptor binding assays
Radioligand-receptor binding assays were used to identify the affinity of Y-QA31 for G protein-coupled receptors, and the protocols were performed according to previous reports [3, 13] with some modifications. The reactions were initiated by adding diluted membranes and were incubated at 25 °C, 30 °C or 37 °C for 30-60 min, depending on the individual assay, until binding reached equilibrium (see Table 1 for details). Non-specific binding was defined in the presence of saturating concentrations of the unlabeled compounds listed in Table 1 . The concentrations of Y-QA31 ranged from 10 -12 to 10 -5 mol/L. Radioactivity bound to filters was quantified by liquid scintillation in a MicroScint-20 (PerkinElmer LAS Ltd, Beaconsfield, UK). IC 50 values were analyzed by nonlinear regression using Prism 5 (GraphPad Software, San Diego, CA, USA). K i values were calculated according to Cheng-Pruss of: [16] . The intrinsic activity (agonist or antagonist) of Y-QA31 on [ 35 S]GTPγS binding was measured in the absence or presence of quinpirole (10 μmol/L) or 8-OH-DPAT (10 μmol/L, a 5-HT 1A receptor agonist). The of Y-QA31 (10 μmol/L) for α 1A adrenoceptor was tested in the absence or presence of norepinephrine (10 μmol/L).
In vivo studies of Y-QA31
Methamphetamine-or MK-801-induced hyperlocomotion and spontaneous locomotion in mice
The day before testing, mice were placed in spontaneous activity chambers (40 cm×40 cm×40 cm) for a 30 min habituation period. On the testing day, the animals were administered either the vehicle or drug 20 min prior to the injection of methamphetamine (0.5 mg/kg, ip) or MK-801 (0.25 mg/kg, ip). A video system was used to track the movement for 1 h and record the horizontal distance traveled. 
Disruption of prepulse inhibition (PPI) by methamphetamine in mice
The procedures used were previously reported by Millan [12] , with some modifications. Male CD1 mice were administered the drug or vehicle 20 min before the injection of methamphetamine (6 mg/kg, ip) or vehicle and then placed individually in the startle chambers connected via an interface to a computer that controlled auditory stimuli and monitored startle responses. The prepulse parameter test session consisted of 4 trial types: startle stimulus trials (pulse-alone), two different prepulse-alone trial types (prepulse-alone), and two different prepulse trial types (prepulse+pulse). The pulse-alone trial type consisted of the presentation of a 20-ms, 115-dB pulse. The two prepulse-alone trial types consisted of 4-ms, 80-dB or 85-dB prepulse stimuli that were randomly administered. The two prepulse+pulse trial types consisted of 80-dB and 85-dB prepulses, followed 30 ms later (the interstimulus interval; the time between prepulse offset and pulse onset) by the 20-ms, 115-dB startle pulse. After a 5 min acclimation period with 65-dB background noise, 10 of the 4 trial types (a total of 40 trials) were presented in a pseudo-random order with an average inter-trial interval of 15 s for a total of 40 trials. PPI was defined as the percentage of reduction in startle amplitude in the presence of prepulse versus the absence of prepulse. %PPI=100-[(startle amplitude for prepulse+pluse)/(startle amplitude for pluse alone)]×100.
Conditioned avoidance responses (CAR) in mice
Mice were trained to avoid an electric shock (0.16 mA, 5 s) by switching compartments of a shuttle box upon the appearance of a light. The mice were trained for 30 trials per day, and the intertrial interval was 15-30 s, randomly administered. Each trial consisted of a 10-s "light on" period. The mouse received a shock if it did not change compartments, or it avoided a shock by switching during the "light on" period. Testing was performed when each mouse learned to avoid the shock in over 24 trials per day. The drug or vehicle was administered 30 min before testing.
Induction of catalepsy in mice
The procedure was performed according to Reavill [10] with some modifications. The tails of the animals were lifted so that the forelimbs could touch the 3-cm-high wooden block top edge. Then, the hind limbs were placed on the desktop gently, and the duration spent in this position was determined. The animals that did not move for more than 30 s were categorized as positive animals. Three independent measurements were obtained, separated by 15-min intervals. The drug or vehicle was administered 30 min before testing.
Novel object recognition (NOR) in mice
The procedure was performed according to Karasawa [14] with some modifications. The task was performed in a 40 cm×50 cm×50 cm chamber. All animals were given a habituation session during which they were left to freely explore the environment for 10 min. No objects were placed in the chamber during the habituation trial. 24 h after habituation, training was conducted by placing individual mice into a chamber for 5 min, in which two identical objects (object A1 and A2) were positioned in two adjacent corners, 10 cm away from the walls. In a short-term memory (STM) test given 1.5 h after training, the mice explored the chamber for 5 min in the presence of one familiar and one novel object. All objects presented had similar textures, colors, and sizes, but distinctive shapes. A recognition index calculated for each animal was expressed by the ratio T B /(T A +T B ) (T A =time spent exploring the familiar object A; T B = time spent exploring the novel object B). Between the trials, the objects were washed with a 10% ethanol solution. Exploration was defined as sniffing or touching the object with the nose and/or forepaws. The mice were administered Y-QA31, haloperidol, or clozapine at the indicated doses (po, once daily) for four days prior to the testing day. On the testing day (5th day), the mice were injected with MK-801 (0.2 mg/kg, ip) with or without one of the abovemention drugs 30 min before the training session.
Statistical analysis
The data were expressed as the mean±SEM. All statistical analyses were performed using Prism 5 (GraphPad Software Incorporate, CA, USA). The statistical significance of the catalepsy data was calculated by Fisher's exact test. Other data were tested by one-way ANOVA or two-way ANOVA to compare the differences among multiple groups. P<0.05 was considered statistically significant. (Figure 2A and Table 2 ). Y-QA31 also bound to the dopamine D 2 R; however, the affinity was much lower (IC 50 =220.2±48.4 nmol/L, K i =52.1±11.1 nmol/L) ( Figure 2A and Table 2 (Figure 3 ). (Figure 4D) , and, by itself, also inhibited spontaneous locomotor activity [F (3, 29) =28.07; P<0.0001] at these doses ( Figure 4B Figure 5C ) and did not affect the escape response. Clozapine also suppressed the avoidance response at 2.5 and 5 mg/kg [F (4, 44) =6.05; P<0.001] ( Figure 5B ) but had the trend to produce the escape response failure at a high dose (5 mg/kg), probably because of its motor side effect. In this experiment, the effect of haloperidol was more potent, which was consistent with a previous report [12] .
Effects of Y-QA31 on PPI in mice Y-QA31 alone had no influence on the basal %PPI at low doses; Y-QA31 at dosage of 40 mg/kg reduced the %PPI by 85-dB prepulse [dB: F (1, 35) Figure 6B ), which was consistent with a previous report [12] .
Effects of Y-QA31 on MK-801-induced NOR disruption in mice
During the training trial, no difference was found among the (Figure 7B ), which was consistent with a previous report [14] .
Y-QA31 induced catalepsy in mice
Within the effective doses of 5-40 mg/kg (po), Y-QA31 did not elicit catalepsy. Induction of catalepsy by Y-QA31 was observed at 120 mg/kg (Table 3) . Clozapine did not induce catalepsy until its dose was over 7.5 mg/kg (Table 3) . Haloperidol elicited potent catalepsy at doses up to 0.64 mg/kg (Table 3 ). Excess dopamine in the brain caused by dysfunction in the dopamine system is considered to be an important mechanism for positive symptoms of schizophrenia. Methamphetamine induces hyperactivity by facilitating the release of dopamine from presynaptic nerve terminals and inhibiting reuptake, which increases extracellular dopamine levels in the brain. For this reason, methamphetamine-induced hyperlocomotion is used as a classic dopaminergic model for the identification of antipsychotics [17] . The current data showed that Y-QA31 inhibited methamphetamine-induced hyperlocomotion at doses lower than those used to inhibit spontaneous locomotion. Thus far, most of the evidence indicates that blocking D 3 R may not inhibit methamphetamine-induced hyperactivity. For example, the selective D 3 R antagonist S33084 did not alter methamphetamine-induced hyperactivity [10, 11] . Furthermore, knocking down D 3 R with mRNA antisense oligodeoxynucleotides [18] or knocking out the receptor entirely results in increased locomotion [19] . By comparison, D 2 R knockout mice [20] . Y-QA31 exerted low potency in inhibiting hyperlocomotion induced by methamphetamine, whereas the D 2 R-selective antagonist haloperidol markedly inhibited hyperlocomotion. One possible explanation for the weak effect of Y-QA31 against methamphetamine might be the low D 2 R occupancy present even at high doses of Y-QA31 (20 mg/kg and 40 mg/kg). In addition, because Y-QA31 binds the α 1A adrenoceptor with medium affinity and the α 1A adrenoceptor may play a role in hyperactivity [21] , another explanation for Y-QA31's weak inhibitory action may due to its α 1A adrenoceptor antagonism.
In comparison with methamphetamine-induced hyperlocomotion, MK-801-induced hyperlocomotion was significantly inhibited by Y-QA31. Previous studies have also found that MK-801-induced hyperactivity is blocked by inhibiting D 3 R [22] , such as using the D 3 R selective antagonist F17141 [23] . The NMDA receptor antagonists PCP, ketamine, and MK-801 produce similar hyperlocomotion as methamphetamine does [24] . However, the mechanism underlying MK-801-induced hyperlocomotion is different from methamphetamine-induced hyperlocomotion, possibly because of an increased release of dopamine and associated activation of the dopamine system in the mesolimbic zone caused by the influence of glutamate [25] . Nakajima et al proposed that D 3 R may control NMDA receptor signaling by acting on pyramidal cells, either directly at postsynaptic levels in the NAc or indirectly at presynaptic levels in the PFC [26] . PPI of the startle reflex is a currently accepted sensorimotor gating model in mammals. Clinical studies have confirmed the phenomenon of disrupted PPI in schizophrenia patients and found that this disruption is related to cognitive deficits such as disordered thought and poor attention [27] . In animal models, PPI disruption can be induced by dopamine agonists, NMDA receptor blockers and 5-HT 2A receptor agonists; pharmacological reversal of PPI disruption indicates antipsychotic potential. Similar to other selective D 3 R antagonists, SB-277011A and A-437203 [28] , Y-QA31 alone did not affect the basal PPI at low doses but increased the PPI at high doses. In the model of methamphetamine-induced PPI disruption, the inhibitory effect of Y-QA31 (5-40 mg/kg) on PPI deficit indicated its antipsychotic effect and also suggested a role for D 3 R in PPI dysfunction. Previous findings showed that PPI dysfunction induced by PD128907, a D 3 R agonist, was reversed by two selective D 3 R antagonists, SB-277011A and A-691990, but not by raclopride or haloperidol, both of which are D 2 R antagonists [29, 30] . SB-277011A also reversed PPI disruption induced by social isolation [10, 30] . However, research in genetically modified mice was not consistent with the pharmacological findings. Amphetamine-induced PPI disruption was unaffected in D 3 R-KO mice but absent in D 2 R-KO mice [31] . Therefore, more research is needed to address the involvement of D 3 R in PPI. Many other receptors are involved in the development of PPI, such as 5-HT 1A receptors and α 1A adrenoceptor [21] . Previous studies showed that 5-HT 1A receptor antagonists attenuate or abolish the PPI disruption induced by MK-801 [32] , 8-OH-DPAT, or apomorphine [33] . Considering Y-QA31's modest affinity for the 5-HT 1A receptor and α 1A adrenoceptor, these receptors may mediate the effects of Y-QA31 on PPI disruption [21] . Additionally, D 2 R antagonism may also contribute to the effect of Y-QA31 on PPI at high doses.
Y-QA31 produced weak suppression of CAR compared with the D 2 R antagonist haloperidol. The behavioral mechanisms of antipsychotic-induced suppression of CAR are still not fully understood, but some evidence suggests that CAR is mediated primarily by D 2 R in the ventral striatum [34] . Generally, 50% D 2 R occupancy is required for CAR suppression [35] . Considering the low D 2 R occupancy of Y-QA31, we speculate that this weak effect may occur because the D 2 R antagonism of Y-QA31 is not strong enough for potent inhibition of CAR. Some evidence suggests that CAR may be at least partially dissociated from D 2 R blockade. The 5-HT 1A and 5-HT 2A receptors, the α 1A adrenoceptor and NMDA receptor may participate in this process [36] . For example, the 5-HT 1A receptor agonist 8-OH-DPAT produced a moderate suppression of CAR [37] . We propose that the moderate 5-HT 1A receptor partial agonism and α 1A adrenoceptor antagonism of Y-QA31 may also contribute to CAR. Thus far, the role of D 3 R in CAR remains unclear.
Cognitive deficit is considered as a core feature of schizophrenia, and it lacks responsiveness to many current antipsychotic drugs. NOR is a form of visual-recognition memory that is dependent on animals' innate preference to investigate novel objects, which is decreased in schizophrenia patients because of their visual-recognition memory impairments [38] . The current study found that NOR was disrupted by MK-801, consistent with previous reports [39, 40] . Y-QA31 (1 mg/kg) significantly alleviated the NOR disruption induced by MK-801, suggesting that blocking D 3 R improved the cognitive and learning dysfunction. It has recently been confirmed that D 3 R plays an important role in cognitive dysfunctions [41, 42] . D 3 R knockout mice exhibit increased cognitive flexibility in the attentional set-shifting task and improved retention in a passive-avoidance test [43] . Moreover, the pharmacological findings also support the potential role of D 3 R in treating cognitive dysfunctions and negative symptoms. For example, D 3 R antagonist S33084 enhances cognitive performance in wildtype mice but not in D 3 R knockout mice [44] . Other D 3 antagonists, such as the highly selective SB-277011A and RGH-1756 and the moderately selective U-99194A, significantly attenuated the learning deficit caused by FG-7142 and scopolamineinduced amnesia [41] . D 2 R antagonists, however, produced deleterious effects or no effect on cognition. For example, L741,626 had no pro-cognitive effect in models on social isolation rearing and the social recognition paradigm [45, 46] . Notably, Y-QA31 was effective in improving cognitive symptoms in the NOR model at 10-fold lower doses than the doses used to attenuate positive symptoms. This phenomenon was also observed in the dual D 2 R/D 3 R antagonist, amisulpride, which controls both cognitive deficit and positive symptoms in the clinic. The effective dose of amisulpride is 50-100 mg per day www.chinaphar.com Sun X et al Acta Pharmacologica Sinica npg when cognitive deficit predominate but 400-800 mg per day when positive symptoms predominate [47, 48] . The mechanism of amisulpride in treating cognitive and positive symptoms with different doses possibly involves its preferential blockade effects of presynaptic or postsynaptic mechanisms and limbic structures. Blocking presynaptic dopamine D 2 /D 3 autoreceptors with low doses of amisulpride induces increased dopaminergic neurotransmission, whereas high doses may block postsynaptic dopaminergic activity. The reason that Y-QA31 treats cognitive deficit and positive symptoms at different doses remains unknown, but preferential binding to presynaptic or postsynaptic receptors is a possible mechanism.
Blockade of D 2 R in the striatum can induce extrapyramidal motor side effects such as catalepsy, whereas D 3 R blockade is unlikely to provoke extrapyramidal side effects. Consistent with this idea, Y-QA31 did not induce catalepsy until dosage reached 120 mg/kg, whereas haloperidol (0.64 mg/kg) and clozapine (7.5 mg/kg) significantly induced catalepsy in therapeutic doses. These results further support the observation that D 3 R blockade is associated with very low incidence of catalepsy. In addition, D 3 R antagonists such as SB-277011A and S33084 were found to inhibit haloperidol-induced catalepsy [49, 50] , which may predict the therapeutic value of D 3 R blockade in the treatment of schizophrenia.
Taken together, Y-QA31 exhibits anti-psychotic effects in some animal models of positive symptoms without inducing the extrapyramidal side effects and the inhibition of spontaneous locomotion compared with haloperidol and clozapine. Moreover, similar to clozapine, Y-QA31 alleviates cognitive dysfunction in the NOR model. Given the high affinity of Y-QA31 to D 3 R, the mechanism of its antipsychotic effect might be associated with D 3 R blockade, but D 2 R, as well as α 1A adrenoceptor antagonism and 5-HT 1A receptor partial agonism, should also be considered. Further pharmacological profiling studies with Y-QA31 could contribute to a more precise understanding of the function of D 3 R or the 5-HT 1A receptor, as well as the α 1A adrenoceptor relevant to schizophrenia.
Conclusions
Y-QA31 is a dopamine D 3 receptor antagonist that also exhibits partial agonism of the 5-HT 1A receptor and antagonism to the α 1A adrenoceptor with medium affinity. Y-QA31 produced antipsychotic effects in some animal models of positive symptoms at high doses and pro-cognitive effects at low doses, with low extrapyramidal syndrome. The results of this study further suggest that D 3 receptor antagonism is still of therapeutic value for treating symptoms of schizophrenia.
